Who are Golimumab Injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ETN+MTX, Akkermansia muciniphila + Infliximab, Adalimumab (Humira), Etanercept (ENBREL®), Infliximab (Remicade), etanercept (EnbrelTM).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/golimumab-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Golimumab Injection — Competitive Intelligence Brief

Golimumab Injection (Golimumab Injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF-α inhibitor (monoclonal antibody). Area: Immunology.

phase 3 TNF-α inhibitor (monoclonal antibody) TNF-α Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Golimumab Injection (Golimumab Injection) — MSD Pharmaceuticals LLC. Golimumab is a monoclonal antibody that binds to and inhibits tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Golimumab Injection TARGET	Golimumab Injection	MSD Pharmaceuticals LLC	phase 3	TNF-α inhibitor (monoclonal antibody)	TNF-α
ETN+MTX	ETN+MTX	Japan Biological Agent Study Integrated Consortium	marketed	TNF inhibitor + DMARD combination	TNF-α receptor; dihydrofolate reductase
Akkermansia muciniphila + Infliximab	Akkermansia muciniphila + Infliximab	Chinese Medical Association	marketed	Combination therapy: probiotic + TNF-α inhibitor	TNF-α (infliximab component); gut microbiota modulation (Akkermansia muciniphila component)
Adalimumab (Humira)	Adalimumab (Humira)	Tufts Medical Center	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (Tumor Necrosis Factor-alpha)
Etanercept (ENBREL®)	Etanercept (ENBREL®)	Amgen	marketed	TNF receptor antagonist	TNF-α and TNF-β
Infliximab (Remicade)	Infliximab (Remicade)	University of California, San Diego	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (Tumor Necrosis Factor-alpha)
etanercept (EnbrelTM)	etanercept (EnbrelTM)	Wyeth is now a wholly owned subsidiary of Pfizer	marketed	TNF receptor antagonist (TNF inhibitor)	TNF-α and TNF-β (tumor necrosis factor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF-α inhibitor (monoclonal antibody) class)

Merck Sharp & Dohme LLC · 3 drugs in this class
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 2 drugs in this class
Hanyang University Seoul Hospital · 2 drugs in this class
Biocad · 1 drug in this class
Children's Memorial Health Institute, Poland · 1 drug in this class
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · 1 drug in this class
Centocor, Inc. · 1 drug in this class
Hikma Pharmaceuticals LLC · 1 drug in this class
Hospital de Manises · 1 drug in this class
Celltrion · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Golimumab Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/golimumab-injection. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab